Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies.
Antares Therapeutics
Private
Antares Therapeutics is a clinical-stage small molecule biopharmaceutical company developing oral and injectable therapies for autoimmune and inflammatory diseases. The company is headquartered in Princeton, New Jersey, and was acquired by Novartis in 2026.
Company Info
Sector:Small Molecule Therapeutics
Headquarters:Princeton, New Jersey, USA
Founded:2020
Website:antaresrx.com/
Funding Round:Acquired by Novartis (2026)
Total Funding:Undisclosed (acquisition terms)
Funding & Investor Relations
IPO Outlook / Plans
N/A (private; acquired)
Upcoming Milestones & Key Dates
2026-07-15
Clinical Readout
Phase 2 ATRS-101 topline readout (psoriasis)
2026-11-08
Conference
AHA Scientific Sessions
Clinical Development Pipeline
ATRS-101
Target: TYK2 inhibitorATRS-202
Target: JAK1-selectiveATRS-303
Target: Allosteric S1P receptor modulatorRecent News
Leadership Team
Amitabh Singh
Chief Executive Officer
Robert Forrester
Chief Operating Officer
Marianne C. Rotschafer
Chief Medical Officer